A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

Yesterday
R&D
In Focus

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

Last week
People
Discovery

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

3 weeks ago
Deals
R&D

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

3 weeks ago
People
AI

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

3 weeks ago
R&D

Still-in-stealth biotech part­ners with Sloan Ket­ter­ing sci­en­tists to make per­son­al­ized can­cer ther­a­py more ‘pub­lic’

4 weeks ago
Discovery
Cell/Gene Tx

As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

4 weeks ago
Deals
Bioregnum

The R&D chal­lenge: 4 top drug hunters talk best prac­tices in build­ing a biotech to­day

4 weeks ago
R&D

Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

4 weeks ago
Deals
Bioregnum

Arie and Dan Bellde­grun are build­ing biotech cam­pus­es around the globe — with a new­ly raised $3B fund to keep the dirt fly­ing

4 weeks ago
Financing

Aviv Regev re­cruits a ‘pur­ple uni­corn’ for the top post in the com­pu­ta­tion­al pil­lar she’s build­ing at Genen­tech

4 weeks ago
Bioregnum
Pharma

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

5 weeks ago
People
Discovery

Scoop: Bridge­Bio's chief strat­e­gy of­fi­cer re­signs as the com­pa­ny qui­et­ly em­barks on an­oth­er round of lay­offs

5 weeks ago
R&D

The End­points R&D 15: How many block­busters does $124B buy the biggest spenders in drug re­search? (Not enough)

5 weeks ago
Special
Pharma

New pa­per sheds fresh light on Tmu­ni­ty's high-pro­file CAR-T deaths

Last month
R&D
Cell/Gene Tx

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

Last month
Special

Guest col­umn: What hap­pened with Es­pe­ri­on — and what de­fines suc­cess or fail­ure?

Last month
Biotech Voices

'Em­pa­thy and love were not shown’: The sto­ry be­hind Taysha’s lay­offs, one of dozens of biotechs suf­fer­ing this year’s bear mar­ket

Last month
Cell/Gene Tx
In Focus

Af­ter Covid-19 suc­cess, pa­tients with the world’s ‘most stig­ma­tized’ in­fec­tion push for their own Op­er­a­tion Warp Speed

Last month
In Focus

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

Last month

Chirps, chats and Club­hous­es: First-time biotech founders turn to so­cial me­dia for ad­vice, in­vestors and re­cruit­ment

Last month
Startups
In Focus

Ex­clu­sive: Fol­low­ing a se­vere set­back, Bridge­Bio brings out the bud­get axe to chop staff but keeps qui­et on the num­bers

Last month
Pharma

Sanofi R&D team ac­cel­er­ates block­buster de­vel­op­ment ef­forts — while cast­ing doubt on a heavy­weight ri­val’s plans

Last month
Bioregnum

In­side the race to make psy­che­delics 'main­stream med­i­ci­nes'

Last month
R&D
In Focus
1234 Next page Last page